EVNIN LUKE sold $47K of HOWL (indirect holdings)

EVNIN LUKE sold 157,084 indirectly-held shares of Werewolf Therapeutics, Inc. (HOWL) at $0.30 on 2026-06-29 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · EVNIN LUKE
Published Jun 29, 2026, 11:07 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 29, 2026, 11:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$HOWL
Neutral
medium confidence
Mentioned
$HOWL
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$HOWLNeutralLow
01

Why it matters

The newest fact is the director’s open-market sale of 157,084 shares at $0.3000/share, leaving 143,199 shares after the transaction.

02

Market read

Traders may note insider selling, but the 10b5-1 structure and lack of other catalysts make this more of a monitoring item than a trade trigger.

03

What to watch

The filing is indirect holdings; without context on total insider ownership changes across time, the incremental signal is limited.

Relevance 2/10Novelty 5/10Timing: filed June 29, 2026 (after-hours/SEC filing timestamp)

Background

The article is an SEC Form 4 insider transaction disclosure for Werewolf Therapeutics, Inc.

Company-level read

Ticker impact

$HOWLNeutralMedium confidence
Context

SEC Form 4 shows director EVNIN LUKE sold 157,084 HOWL shares in an open-market transaction under a 10b5-1 plan.

Expected impact

Likely limited immediate price impact; any effect would be sentiment-driven and small versus broader fundamentals.

Evidence & confidence

The filing is a routine insider sale (code S) with a pre-arranged 10b5-1 plan, and the article provides no new operational/regulatory/financial catalyst.

Market effects

No sector read-across; this is a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect liquidity planning rather than bearish expectations.

Key entities

  • Werewolf Therapeutics, Inc.

    Subject of the Form 4 insider transaction disclosure (HOWL).

  • EVNIN LUKE

    Director who sold shares under a pre-arranged 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$HOWLMedAI 8/10

Werewolf Therapeutics’ Clinical Data for WTX-124 and WTX-330 Presented at the Society for Immunotherapy of Cancer’s (SITC) 2026 Annual Meeting

Werewolf Therapeutics, Inc. (HOWL) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Werewolf Therapeutics’ Clinical Data for WTX-124 and WTX-330 Presented at the Society for Immunotherapy of Cancer’s (SITC) 2026 Annual Meeting – In a Phase 1/1b clinical trial , WTX-124 was administered safely at its recommended Phase 2 dose of 18 mg IV Q2W in the ou